Structural basis for progression toward the carbapenemase activity in the GES family of β-lactamases.

Carbapenem antibiotics have become therapeutics of last resort for the treatment of difficult infections. The emergence of class-A β-lactamases that have the ability to inactivate carbapenems in the past few years is a disconcerting clinical development in light of the diminished options for treatment of infections. A member of the GES-type β-lactamase family, GES-1, turns over imipenem poorly, but the GES-5 β-lactamase is an avid catalyst for turnover of this antibiotic. We report herein high-resolution X-ray structures of the apo GES-5 β-lactamase and the GES-1 and GES-5 β-lactamases in complex with imipenem. The latter are the first structures of native class-A carbapenemases with a clinically used carbapenem antibiotic in the active site. The structural information is supplemented by information from molecular dynamics simulations, which collectively for the first time discloses how the second step of catalysis by these enzymes, namely, hydrolytic deacylation of the acyl-enzyme species, takes place effectively in the case of the GES-5 β-lactamase and significantly less so in GES-1. This information illuminates one evolutionary path that nature has taken in the direction of the inexorable emergence of resistance to carbapenem antibiotics.

[1]  R. Flamm,et al.  Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. , 2011, The Journal of antimicrobial chemotherapy.

[2]  K. Bush Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. , 2010, Current opinion in microbiology.

[3]  R. Arora,et al.  Delirium as a predictor of sepsis in post-coronary artery bypass grafting patients: a retrospective cohort study , 2010, Critical care.

[4]  K. Bush Bench-to-bedside review: The role of β-lactamases in antibiotic-resistant Gram-negative infections , 2010, Critical care.

[5]  S. Mobashery,et al.  Mechanistic Basis for the Emergence of Catalytic Competence against Carbapenem Antibiotics by the GES Family of β-Lactamases , 2009, The Journal of Biological Chemistry.

[6]  R. Bonomo,et al.  Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. , 2008, Journal of the American Chemical Society.

[7]  T. Walsh Clinically significant carbapenemases: an update , 2008, Current opinion in infectious diseases.

[8]  N. Høiby,et al.  Class A carbapenemases. , 2007, The Journal of antimicrobial chemotherapy.

[9]  K. Bush,et al.  Carbapenemases: the Versatile β-Lactamases , 2007, Clinical Microbiology Reviews.

[10]  N. Sahinidis,et al.  An integer minimal principle and triplet sieve method for phasing centrosymmetric structures. , 2007, Acta crystallographica. Section A, Foundations of crystallography.

[11]  Samy O Meroueh,et al.  Ab initio QM/MM study of class A beta-lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70. , 2005, Journal of the American Chemical Society.

[12]  Samy O Meroueh,et al.  Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. , 2005, Chemical reviews.

[13]  Laurent Maveyraud,et al.  Structural Basis for Clinical Longevity of Carbapenem Antibiotics in the Face of Challenge by the Common Class A Beta-Lactamases from Antibiotic-Resistant Bacteria , 1998 .

[14]  K. Bush,et al.  How β-Lactamases Have Driven Pharmaceutical Drug Discovery , 1998 .

[15]  S. Mobashery,et al.  Facilitation of the .DELTA.2 .fwdarw. .DELTA.1 pyrroline tautomerization of carbapenem antibiotics by the highly conserved arginine-244 of class A .beta.-lactamases during the course of turnover , 1992 .

[16]  J M Ghuysen,et al.  A standard numbering scheme for the class A beta-lactamases. , 1991, The Biochemical journal.